FDA panel picks JN.1 subvariant for fall COVID vaccines

The expert advisory panel for the Food and Drug Administration (FDA) unanimously voted on Wednesday in favor of selecting the JN.1 COVID-19 subvariant to be targeted by the next round of COVID-19 vaccines this fall. The FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) was asked if it would recommended a monovalent vaccine that...